MA50033A - Composés macrocycliques permettant d'inhiber la protéine mcl-1 - Google Patents
Composés macrocycliques permettant d'inhiber la protéine mcl-1Info
- Publication number
- MA50033A MA50033A MA050033A MA50033A MA50033A MA 50033 A MA50033 A MA 50033A MA 050033 A MA050033 A MA 050033A MA 50033 A MA50033 A MA 50033A MA 50033 A MA50033 A MA 50033A
- Authority
- MA
- Morocco
- Prior art keywords
- protein
- macrocyclic compounds
- inhibit mcl
- mcl
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551718P | 2017-08-29 | 2017-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50033A true MA50033A (fr) | 2020-07-08 |
Family
ID=63528919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050033A MA50033A (fr) | 2017-08-29 | 2018-08-27 | Composés macrocycliques permettant d'inhiber la protéine mcl-1 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11279712B2 (fr) |
| EP (1) | EP3676270A1 (fr) |
| MA (1) | MA50033A (fr) |
| WO (1) | WO2019046150A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| EP3668878A1 (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Composés inhibant la protéine mcl-1 |
| WO2019173181A1 (fr) | 2018-03-05 | 2019-09-12 | Amgen Inc. | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
| DK3793565T3 (en) | 2018-05-14 | 2022-03-07 | Gilead Sciences Inc | Mcl-1-inhibitorer |
| EP3781574B1 (fr) * | 2019-01-18 | 2023-05-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Spiroéthers macrocycliques utilisés en tant qu'inhibiteurs de mcl-1 |
| EP3997097B1 (fr) | 2019-07-09 | 2024-03-20 | Janssen Pharmaceutica NV | Dérivés spirocycliques macrocycliques en tant qu'inhibiteurs de mcl-1 |
| TWI778443B (zh) * | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN114787139A (zh) | 2019-11-26 | 2022-07-22 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
| WO2021250102A1 (fr) | 2020-06-10 | 2021-12-16 | Janssen Pharmaceutica Nv | 2-amino-3-fluoro-but-3-énamides macrocycliques utilisés comme inhibiteurs de mcl-1 |
| KR20230121806A (ko) | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 분지형 3-플루오로-부트-3-엔아미드 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| CA3222269A1 (fr) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 en combinaison avec des agents anticancereux |
| WO2022261310A1 (fr) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 en combinaison avec des conjugués anti-corps-médicament |
| CA3237011A1 (fr) | 2021-11-16 | 2023-05-25 | Soufyan JERHAOUI | 2-amino-but-3-enamides macrocycliques utilises en tant qu'inhibiteurs de mcl-1 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| MY162157A (en) | 2007-04-16 | 2017-05-31 | Abbott Lab | Substituted indole mcl-1 inhibitors |
| AU2011210567B2 (en) | 2010-01-29 | 2015-04-16 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of MCL-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders |
| WO2013052943A2 (fr) | 2011-10-06 | 2013-04-11 | The Regents Of The University Of Michgian | Inhibiteurs à petite molécule de mcl-1 et leurs utilisations |
| ES2657649T3 (es) | 2012-03-29 | 2018-03-06 | The Regents Of The University Of Michigan | Inhibidores de Mcl-1 de molécula pequeña y sus usos |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| US11306107B2 (en) * | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| EP3668878A1 (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Composés inhibant la protéine mcl-1 |
| WO2019173181A1 (fr) | 2018-03-05 | 2019-09-12 | Amgen Inc. | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
-
2018
- 2018-08-27 WO PCT/US2018/048058 patent/WO2019046150A1/fr unknown
- 2018-08-27 MA MA050033A patent/MA50033A/fr unknown
- 2018-08-27 US US16/642,441 patent/US11279712B2/en active Active
- 2018-08-27 EP EP18766453.7A patent/EP3676270A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3676270A1 (fr) | 2020-07-08 |
| US11279712B2 (en) | 2022-03-22 |
| US20200247821A1 (en) | 2020-08-06 |
| WO2019046150A1 (fr) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50033A (fr) | Composés macrocycliques permettant d'inhiber la protéine mcl-1 | |
| DK3601297T3 (da) | Forbindelser, der hæmmer mcl-1-protein | |
| DK3668855T3 (da) | Herbicide forbindelser | |
| MA49908A (fr) | Composés inhibant la protéine mcl-1 | |
| DK3728252T3 (da) | 4-azaindolforbindelser | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| DK3612519T3 (da) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser | |
| BR112017014839A2 (pt) | novos microbicidas | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| DK3601691T3 (da) | Skillevæg | |
| IT201700053475A1 (it) | Calzatura componibile | |
| DK3672941T3 (da) | Pyridylpyridonforbindelser | |
| MA49885A (fr) | Composés macrocycliques | |
| DK3445766T3 (da) | Ny antimikrobiel forbindelse | |
| DK3412667T3 (da) | Cokrystal | |
| DK3894410T3 (da) | Substituerede xanthinderivater | |
| DK3672962T3 (da) | Morpholinylpyridonforbindelser | |
| ITUA20163609A1 (it) | "micro-cogeneratore". | |
| MA54534A (fr) | Antagonistes | |
| TH185039B (th) | ไม้แขวนเสื้อ | |
| JP1631865S (ja) | 靴 | |
| JP1631866S (ja) | 靴 | |
| FR3087334B1 (fr) | Cage interosseuse | |
| UA36135S (uk) | Балансир для ловлі риби | |
| UA39587S (uk) | Шафа |